Sucralfate

(Antepsin*, Antepsin suspension*, Carafate*, Sulcrate*) POM

- **Client Information Leaflet:** Sucralfate
- **Formulations**

Oral: 1 g tablets; 0.2 g/ml suspension.

- **Action**

In an acidic medium an aluminium ion detaches from the compound, leaving a very polar, relatively non-absorbable ion. This ion then binds to proteinaceous exudates in the upper GI tract, forming a chemical diffusion barrier over ulcer sites, preventing further erosion from acid, pepsin and bile salts. However, its major action appears to relate to stimulation of mucosal defences and repair mechanisms (stimulation of bicarbonate and prostaglandin production and binding of epidermal growth factor). These effects are seen at neutral pH.

More +

- **Use**
    - Treatment of oesophageal, gastric and duodenal ulceration.
    - Not recommended as a phosphate binder in chronic kidney disease.

Can be used alongside an H2 receptor antagonist or proton-pump inhibitor but should be given separately.

- **DOSES**
    - **Dogs: All uses:** 500 mg/dog p.o. q6–8h (dogs <20 kg); 1–2 g/dog p.o. q6–8h (dogs >20 kg).
    - **Cats: All uses:** 250 mg/cat p.o. q8–12h.